Recap: MainStreet Bancshares Q2 Earnings

  MainStreet Bancshares (NASDAQ:MNSB) reported its Q2 earnings results on Monday, July 25, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

 

MainStreet Bancshares (NASDAQ:MNSB) reported its Q2 earnings results on Monday, July 25, 2022 at 08:00 AM.

Here’s what investors need to know about the announcement.

Earnings

MainStreet Bancshares beat estimated earnings by 9.23%, reporting an EPS of $0.71 versus an estimate of $0.65.

Revenue was up $2.84 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.08 which was followed by a 2.94% increase in the share price the next day.

Here’s a look at MainStreet Bancshares’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 0.56 0.58 0.55 0.57
EPS Actual 0.64 0.56 0.56 0.87
Revenue Estimate 13.66M 13.37M 12.60M 13.50M
Revenue Actual 16.36M 15.49M 14.69M 14.55M

Listen to the earnings announcement yourself by clicking here.

To track all earnings releases for MainStreet Bancshares visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Take-Two Interactive Offers A Scaled Portfolio Of Mobile Games, Says Analyst

J.P. Morgan maintains an Overweight rating on Take-Two Interactive with a $200 target, citing positive trends in mobile gaming, particularly for Zynga. Management expresses confidence in mobile market growth and stability into 2024, highlighting consumer readiness to invest in new games.

TTWO

Read More

Sanofi and Innate Pharma Earlier Announced Expanded Collaboration for Natural Killer Cell Therapeutics in Oncology; Innate Will Receive €25M Upfront; Up to €1.35B in Milestones Plus Royalties on Potential Net Sales

Sanofi (NASDAQ: SNY) and Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced today an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate's ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform.

IPHA